Certara (NASDAQ:CERT – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01), FiscalAI reports. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same period in the previous year, the business earned $0.07 EPS. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis.
Here are the key takeaways from Certara’s conference call:
- Second-quarter revenue grew 1% to $93.3 million, with software revenue up 4% and services revenue down 3%. Management reaffirmed full-year revenue growth guidance of 0%–4%, or $367 million–$382 million on a continuing-operations basis.
- Software bookings increased 9% in the quarter and trailing-12-month software bookings rose 8%, supported by Simcyp, Phoenix and Pinnacle 21. The company also reported a 27% year-over-year increase in pipeline and expects software revenue to reach at least the high end of its annual growth range.
- Certara is implementing a new commercial model, appointing Julien Perrier as Chief Commercial Officer and emphasizing specialist-led services sales. A May workforce reduction affecting about 5% of employees is expected to generate approximately $13 million in annualized savings, helping offset stranded costs from the divestiture and fund AI investment.
- Services bookings declined 6% in the second quarter, and management expects full-year services revenue to be at or below the low end of its 0%–4% growth range. Adjusted EBITDA margin guidance was reduced to 29%–31%, while the company posted a $6.1 million continuing-operations net loss versus $1.5 million of income in the prior-year quarter.
- The board authorized an additional $50 million share-repurchase program after Certara completed a prior $100 million authorization. Management also highlighted growing cloud adoption, AI-enabled product development and partnerships—including NVIDIA—as longer-term growth opportunities.
Certara Stock Up 1.8%
Shares of CERT traded up $0.14 during mid-day trading on Thursday, hitting $8.15. 345,388 shares of the company traded hands, compared to its average volume of 3,728,124. The company has a market capitalization of $1.27 billion, a PE ratio of -18.14 and a beta of 1.44. Certara has a 1-year low of $4.45 and a 1-year high of $13.88. The company has a quick ratio of 1.88, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The business has a 50 day moving average of $6.47 and a 200 day moving average of $6.55.
Institutional Investors Weigh In On Certara
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on CERT. Morgan Stanley reduced their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets dropped their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Craig Hallum lowered their price target on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Finally, Stephens lowered their target price on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.95.
View Our Latest Analysis on CERT
About Certara
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
See Also
- Five stocks we like better than Certara
- Why Brown-Forman Rejected a 23% Premium Twice
- Rocket Lab Lands a Wave of Contracts Ahead of Earnings
- Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next?
- Boeing’s Comeback Is Building Momentum—Is It Real?
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
